ResMed Valuation
Is R1MD34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of R1MD34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: R1MD34 (R$235.92) is trading above our estimate of fair value (R$232.31)
Significantly Below Fair Value: R1MD34 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for R1MD34?
Other financial metrics that can be useful for relative valuation.
| What is R1MD34's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$26.99b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.3x |
| Enterprise Value/EBITDA | 20.6x |
| PEG Ratio | 2.2x |
Price to Earnings Ratio vs Peers
How does R1MD34's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 44.3x | ||
RDOR3 Rede D'Or São Luiz | 27.6x | 25.4% | R$54.9b |
4543 Terumo | 38.9x | 12.1% | JP¥3.9t |
STMN Straumann Holding | 86.5x | 23.6% | CHF21.3b |
ZBH Zimmer Biomet Holdings | 24x | 8.5% | US$24.9b |
R1MD34 ResMed | 30.3x | 13.5% | R$27.0b |
Price-To-Earnings vs Peers: R1MD34 is good value based on its Price-To-Earnings Ratio (30.3x) compared to the peer average (44.3x).
Price to Earnings Ratio vs Industry
How does R1MD34's PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Earnings vs Industry: R1MD34 is expensive based on its Price-To-Earnings Ratio (30.3x) compared to the Global Medical Equipment industry average (27.6x).
Price to Earnings Ratio vs Fair Ratio
What is R1MD34's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 30.3x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate R1MD34's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.